Krystal Biotech EBITDA vs. Price To Book
| KRYS Stock | USD 196.52 1.96 1.01% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 17.9 M | Current Value 18.8 M | Quarterly Volatility 40.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.72 | 0.85 |
|
|
For Krystal Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Krystal Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Krystal Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Krystal Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Krystal Biotech over time as well as its relative position and ranking within its peers.
Krystal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Earnings Share 1.77 | Revenue Per Share 8.49 | Quarterly Revenue Growth 8.799 | Return On Assets 0.0458 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Krystal Biotech Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Krystal Biotech's current stock value. Our valuation model uses many indicators to compare Krystal Biotech value to that of its competitors to determine the firm's financial worth. Krystal Biotech is currently regarded as number one stock in ebitda category among its peers. It is rated fourth overall in price to book category among its peers . The ratio of EBITDA to Price To Book for Krystal Biotech is about 2,834,391 . At this time, Krystal Biotech's EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Krystal Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Krystal Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Krystal Biotech |
| = | 17.9 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Krystal Biotech |
| = | 6.32 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Krystal Price To Book Comparison
Krystal Biotech is currently under evaluation in price to book category among its peers.
Krystal Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Krystal Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Krystal Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Krystal Biotech's change in net profit over the period of time. It can combine multiple indicators of Krystal Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 638 K | 669.9 K | |
| Net Interest Income | 22.6 M | 23.8 M | |
| Interest Income | 22.6 M | 23.8 M | |
| Operating Income | -109.7 M | -104.2 M | |
| Net Income From Continuing Ops | 10.9 M | 11.5 M | |
| Income Before Tax | 12.9 M | 13.5 M | |
| Total Other Income Expense Net | 122.6 M | 128.8 M | |
| Net Loss | -126 M | -119.7 M | |
| Net Income | 10.9 M | 11.5 M | |
| Income Tax Expense | 2 M | 1.9 M | |
| Non Operating Income Net Other | -2.8 M | -3 M | |
| Change To Netincome | 37.4 M | 39.3 M | |
| Net Income Per Share | 0.40 | 0.42 | |
| Income Quality | (8.12) | (7.72) | |
| Net Income Per E B T | 0.76 | 0.68 |
Krystal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Krystal Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Krystal Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Krystal Biotech's important profitability drivers and their relationship over time.
Use Krystal Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.Krystal Biotech Pair Trading
Krystal Biotech Pair Trading Analysis
The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Krystal Biotech position
In addition to having Krystal Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronic Equipment Thematic Idea Now
Electronic Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.